RNAC (STOCKS)
Cartesian Therapeutics, Inc. Common Stock
$5.930000
-0.050000 (-0.84%)
Prev close: $5.980000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Carsten Brunn
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $157.60M
- Employees
- 66
- P/E (TTM)
- -1.18
- P/B (TTM)
- -1.22
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
5
Strong Buy
7
Buy
3
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Dec 2025 (Q4)
|
$-3.57 | $-0.87 | -2.6996 | -310.16% |
|
Sep 2025 (Q3)
|
$-1.38 | $-0.86 | -0.5181 | -60.11% |
|
Jun 2025 (Q2)
|
$0.50 | $-0.83 | +1.3262 | +160.52% |
|
Mar 2025 (Q1)
|
$-0.68 | $-0.72 | +0.0398 | +5.53% |
Financial Statements
| Revenues | $2.80M |
| Benefits Costs and Expenses | $142.29M |
| Costs And Expenses | $142.29M |
| Nonoperating Income/Loss | $3.91M |
| Operating Expenses | $146.20M |
| Research and Development | $58.03M |
| Other Operating Expenses | $88.17M |
| Operating Income/Loss | -$143.41M |
| Income/Loss From Continuing Operations After Tax | -$130.30M |
| Income/Loss From Continuing Operations Before Tax | -$139.50M |
| Income Tax Expense/Benefit | -$9.19M |
| Income Tax Expense/Benefit, Deferred | -$9.19M |
| Net Income/Loss | -$130.30M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$130.30M |
| Net Income/Loss Available To Common Stockholders, Basic | -$130.30M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$5.02 |
| Diluted Earnings Per Share | -$5.02 |
| Basic Average Shares | 25,973,329 |
| Diluted Average Shares | 25,973,329 |
| Assets | $296.41M |
| Current Assets | $129.28M |
| Noncurrent Assets | $167.14M |
| Fixed Assets | $12.19M |
| Other Non-current Assets | $154.95M |
| Liabilities | $422.65M |
| Current Liabilities | $14.94M |
| Accounts Payable | $1.29M |
| Wages | $3.99M |
| Other Current Liabilities | $9.66M |
| Noncurrent Liabilities | $407.71M |
| Equity | -$126.24M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | -$126.24M |
| Temporary Equity | $0.00 |
| Temporary Equity Attributable To Parent | $0.00 |
| Liabilities And Equity | $296.41M |
| Net Cash Flow From Operating Activities | -$73.94M |
| Net Cash Flow From Operating Activities, Continuing | -$73.94M |
| Net Cash Flow From Investing Activities | -$5.45M |
| Net Cash Flow From Investing Activities, Continuing | -$5.45M |
| Net Cash Flow From Financing Activities | -$8.06M |
| Net Cash Flow From Financing Activities, Continuing | -$8.06M |
| Exchange Gains/Losses | $45.00K |
| Net Cash Flow | -$87.41M |
| Net Cash Flow, Continuing | -$87.45M |
| Comprehensive Income/Loss | -$130.26M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$130.26M |
| Other Comprehensive Income/Loss | -$130.26M |